Pearcey RG - Search Results

1

Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction.

Wu JS, Brasher PM, El-Gayed A, Pervez N, Tai PT, Robinson J, Skarsgard D, Joseph K, Sia MA, Pearcey RG. Wu JS, et al. Among authors: pearcey rg. Radiother Oncol. 2012 May;103(2):210-6. doi: 10.1016/j.radonc.2011.12.020. Epub 2012 Jan 24. Radiother Oncol. 2012. PMID: 22280805 Clinical Trial.

2

Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers.

Skarsgard D, Cadman P, El-Gayed A, Pearcey R, Tai P, Pervez N, Wu J. Skarsgard D, et al. Radiat Oncol. 2010 Jun 10;5:52. doi: 10.1186/1748-717X-5-52. Radiat Oncol. 2010. PMID: 20537161 Free PMC article. Clinical Trial.

3

Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer.

Wang MH, Vos LJ, Yee D, Patel S, Pervez N, Parliament M, Usmani N, Danielson B, Amanie J, Pearcey R, Ghosh S, Field C, Fallone BG, Murtha AD. Wang MH, et al. Pract Radiat Oncol. 2021 Sep-Oct;11(5):384-393. doi: 10.1016/j.prro.2021.02.011. Epub 2021 Mar 9. Pract Radiat Oncol. 2021. PMID: 33705985 Clinical Trial.

4

Conventional Versus Hypofractionated Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24-Month Patient-Reported Outcomes of the Randomized Phase 2 CHIRP Trial.

Yang F, Ghosh S, Yee D, Patel S, Pervez N, Parliament M, Usmani N, Danielson B, Amanie J, Pearcey R, Field C, Fallone G, Murtha A. Yang F, et al. Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):99-107. doi: 10.1016/j.ijrobp.2022.04.045. Epub 2022 May 7. Int J Radiat Oncol Biol Phys. 2022. PMID: 35537578 Clinical Trial.

5

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R. Pervez N, et al. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):57-64. doi: 10.1016/j.ijrobp.2009.01.048. Int J Radiat Oncol Biol Phys. 2010. PMID: 19395192 Clinical Trial.

6

Development of indicators of the quality of radiotherapy for localized prostate cancer.

Danielson B, Brundage M, Pearcey R, Bass B, Pickles T, Bahary JP, Foley K, Mackillop W. Danielson B, et al. Radiother Oncol. 2011 Apr;99(1):29-36. doi: 10.1016/j.radonc.2011.02.013. Epub 2011 Mar 30. Radiother Oncol. 2011. PMID: 21458094

7

Late Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment.

Pervez N, Boychak A, Drodge CS, Yee D, Le D, Murtha A, Parliament M, Amanie J, Mihai A, Field C, Mackenzie M, Ghosh S, Fallone G, Pearcey R. Pervez N, et al. Am J Clin Oncol. 2017 Apr;40(2):200-206. doi: 10.1097/COC.0000000000000133. Am J Clin Oncol. 2017. PMID: 25268067 Clinical Trial.

8

Assessment of extended-field radiotherapy for stage IIIC endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and helical tomotherapy.

Lian J, Mackenzie M, Joseph K, Pervez N, Dundas G, Urtasun R, Pearcey R. Lian J, et al. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):935-43. doi: 10.1016/j.ijrobp.2007.10.021. Epub 2007 Dec 31. Int J Radiat Oncol Biol Phys. 2008. PMID: 18164828

9

Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression.

Pervez N, Krauze AV, Yee D, Parliament M, Mihai A, Ghosh S, Joseph K, Murtha A, Amanie J, Kamal M, Pearcey R. Pervez N, et al. Curr Oncol. 2012 Jun;19(3):e201-10. doi: 10.3747/co.19.915. Curr Oncol. 2012. PMID: 22670110 Free PMC article.

10

Post-operative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer.

Pearcey RG, Petereit DG. Pearcey RG, et al. Radiother Oncol. 2000 Jul;56(1):17-22. doi: 10.1016/s0167-8140(00)00171-7. Radiother Oncol. 2000. PMID: 10869750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters